Latest Commercialisation News

Blue Star Helium Limited is poised to become a key U.S. helium and natural CO2 producer with first production from its Galactica project scheduled for December 2025. The company’s staged development plan and strategic joint venture position it to address growing domestic helium demand amid global supply constraints.

Audio Pixels Holdings has extended the maturity of $12.3 million in convertible notes to January 2027 and capitalised $4.05 million in accrued interest, enhancing its financial flexibility.

BCAL Diagnostics has launched a $10 million convertible note facility, with $5 million already committed, to strengthen its capital position and accelerate commercialisation of its cancer detection technologies.

Metal Powder Works Limited (MPW) has landed a $1 million contract with the US Navy for its innovative expeditionary DirectPowder™ unit, while expanding its alloy portfolio and customer base amid a $15 million capital raise.

Wide Open Agriculture has developed a novel lupin protein milk formulation that overcomes longstanding technological hurdles, lodging a patent to protect its innovation and gearing up for global commercialisation.

Locksley Resources has produced the first 100% American made antimony ingot in decades, validating a fully domestic mine-to-metal supply chain and advancing U.S. critical minerals independence.

BCAL Diagnostics has established a $10 million convertible note facility, with $5 million already committed, to accelerate its cancer detection technologies and commercial milestones.

Aquirian Limited has secured a $2.3 million strategic placement with Topgroup and signed a non-binding Memorandum of Understanding to form Drillforce WA, a 50 – 50 joint venture combining their drilling and blasting expertise.

Vectus Biosystems has agreed to sell its VB4-P5 renal fibrosis compound to Canadian biotech XORTX Therapeutics for US$3 million in shares and warrants, gaining a strategic equity position while refocusing on its cardiovascular and fibrosis pipeline.

PARKD Limited has successfully closed its Share Purchase Plan, raising $220,000; well above the initial $120,000 target; following a recent $780,000 placement. This capital boost underscores strong shareholder confidence in the company’s innovative building solutions.

Archer Materials has entered a strategic collaboration with Emergence Quantum to fast-track the development of graphene-based quantum devices, aiming to bridge cutting-edge science with commercial applications.

Orthocell has raised $30 million through an institutional placement to accelerate the US commercialisation of its flagship nerve repair product Remplir and expand its regenerative medicine portfolio.